Apexigen, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Apexigen, Inc. - overview
Established
2010
Location
San Carlos, CA, US
Primary Industry
Biotechnology
About
Apexigen, Inc. develops innovative immuno-oncology therapeutics, focusing on antibody-based products designed to enhance cancer treatment efficacy and improve patient outcomes. Founded in 2010 in San Carlos, US, Apexigen, Inc. specializes in immuno-oncology.
The company was acquired by Pyxis Oncology, Inc. on May 24, 2023, for USD 16 mn. The CEO, Xiaodong Yang, leads the firm, which has closed 9 deals overall. Apexigen’s headquarters are in San Carlos, California.
Apexigen specializes in developing immuno-oncology therapeutics, primarily focusing on antibody-based products. Their lead product targets the immune checkpoint protein PD-1, aiming to activate the immune response against tumors in patients with various cancers. Their products are marketed to healthcare providers in North America, Europe, and parts of Asia, addressing an increasing need for effective cancer therapies. Apexigen's revenue model is based on strategic partnerships for developing and commercializing therapeutics.
The company engages in B2B transactions with pharmaceutical firms and research institutions, focusing on milestone payments and royalties from sales of its antibody-based therapies. Following its acquisition by Pyxis Oncology, Inc. , Apexigen will support the expansion of its clinical pipeline into Phase 2 for select solid tumor types, leveraging its immuno-oncology expertise. The latest funding will facilitate this strategic push, aimed at enhancing their clinical offerings in the immuno-oncology sector.
Specific new products are currently under development, although no detailed release dates have been disclosed.
Current Investors
Decheng Capital, SV Tech Ventures, Virtus Inspire Ventures
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.apexigen.com
Company Stage
Add-on
Total Amount Raised
Subscriber access only
Apexigen, Inc. - financials
| Fiscal Year Ended | Dec 31, 2021 | Dec 31, 2022 |
|---|---|---|
| Revenue (USD) | - | - |
| % Revenue Growth (YoY) | - | - |
| EBITDA (USD) | - | - |
| Operating Income (USD) | - | - |
| Operating Margin | - | - |
| % EBITDA Margin | - | - |
| NET Income (USD) | - | - |
| % Net Margin | - | - |
Apexigen, Inc. - employee data
Apexigen, Inc. - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| Board Member | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.